The cost-effectiveness of patient-applied treatments for anogenital warts

International Journal of STD and AIDS

Volumn 14, Issue 4, 2003, Pages 228-234

  Williams, Paul ^a   Von Krogh, Geo ^b  

^a PAREXEL INTERNATIONAL   (United States)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Anogenital warts; Cost effectiveness; Imiquimod; Podophyllotoxin; Self treatment

Indexed keywords

IMIQUIMOD; PLACEBO; PODOPHYLLOTOXIN; WARTICON;

CLINICAL TRIAL; CONDYLOMA; COST EFFECTIVENESS ANALYSIS; CREAM; DRUG COST; DRUG EFFICACY; FOLLOW UP; HEALTH CARE COST; HUMAN; PRIORITY JOURNAL; REMISSION; REVIEW; SELF MEDICATION; VERRUCA VULGARIS;

AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; COST-BENEFIT ANALYSIS; HUMANS; IMMUNOCOMPETENCE; PODOPHYLLOTOXIN; SELF CARE; WARTS;

EID: 0037386129     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/095646203321264827     Document Type: Review

References (35)

1. Koutsky I. Epidemiology of human papillomavirus infection. Am J Med 1997;102:3-8
2. Walboomers JMM, Jacobs MV, Manos MM, et al. Human papilloma virus: a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19
3. Dillner J, Meijer C, von Krogh G, Horenblas S. Epidemiology of human papillomavirus infection. Scand J Urol Nephrol (Suppl) 2000;205:194-200
4. Syrjänen KJ, Stina S (eds). Papillomavirus infections in human pathology. Chichester: John Wiley & Sons Ltd, 2000
5. Hughes G, Simms I, Rogers PA, Swan AV, Catchpole M. New cases seen at genitourinary medicine clinics: England 1997. Common Dis Rep CDR Suppl 1998;8:S2-11
6. Clarke P, Ebel C, Cototti D, Stewart S. The psychosexual impact of human papillomavirus infection: implications for healthcare providers. Int J STD AIDS 1996;7:197-200
7. Maw RD, Reitano M, Roy M. An international survey of patients with genital warts; perceptions regarding treatment and impact on lifestyle. Int J STD AIDS 1998;9:571-8
8. Association of Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases. National guidelines for the management of anogenital warts. Sex Transm Infect 1999;75(Suppl. 1):S71-5
9. von Krogh G, Lacey CJN, Gross G, Barasso R, Schneider A. European course on HPV associated pathology: guidelines for primary care physicians for the diagnosis and management of anogenital warts. Sex Transm Infect 2000;76:162-8
10. Maw R, von Krogh G. The management of anogenital warts. BMJ 2000;321:910-11
11. Langley PC, Richwald GA, Smith MH. Modeling the impact of treatment options in genital warts: patient-applied versus physician-administered therapies. Clin Ther 1999;21:2143-55
12. Beutner KR, Conant MA, Friedman-Kien AE, et al. Patient-applied podofilox for treatment of genital warts. Lancet 1989;8642:831-4
13. Greenberg MD, Rutledge LH, Reid R, Berman NR, Precop SL, Elswick RK. A double-blind, randomized trial of 0.5% podofilox and placebo for the treatment of genital warts in women. Obstet Gynecol 1991;77:735-9
14. Kirby P, Dunne A, King DH, Corey L. Double-blind randomized clinical trial of self-administered podofilox solution versus vehicle in the treatment of genital warts. Am J Med 1990;88:465-9
15. Syed TA, Lundin S, Ahmad SA. Topical 0.3% and 0.5% podophyllotoxin cream for self-treatment of condylomata acuminata in women. A placebo-controlled, double-blind study. Dermatol 1994;189:142-5
16. Syed TA, Cheema KM, Khayyami M, et al. Human leukocyte interferon-alpha versus podophyllotoxin in cream for the treatment of genital warts in males. A placebo-controlled, double-blind, comparative study. Dermatol 1995;191:129-32
17. Syed TA, Khayyami M, Kriz D, et al. Management of genital warts in women with human leukocyte interferon-alpha vs. podophyllotoxin in cream: a placebo-controlled, double-blind, comparative study. J Mol Med 1995;73:255-8
18. Tyring SK, Edwards L, Cherry LK et al. Safety and efficacy of 0.5% podofilox gel in the treatment of anogenital warts. Arch Dermatol 1998;134:33-8
19. von Krogh G, Hellberg D. Self-treatment using a 0.50% podophyllotoxin cream of external genital condylomata acuminata in women. Sex Transm Dis 1992;19:170-4
20. von Krogh G, Szpak E, Andersson M, Bergelin I. Self-treatment using 0.25%-0.50% podophyllotoxin-ethanol solutions against penile condylomata acuminata: a placebo-controlled comparative study. Genitourin Med 1994;70:105-9
21. Moore RA, Edwards JE, Hopwood J, Hicks D. Imiquimod for the treatment of genital warts: a quantitative systematic review. BMC Inf Dis 2001;1:3. http://www.biomedcentral.com/1471-2334/1/3
22. Beutner KR, Spruance SL, Hougham AJ, Fox TL, Owens ML, Douglas JM. Treatment of genital warts with an immune-response modifier (imiquimod). J Am Acad Dermatol 1998;38:230-9
23. Beutner KR, Tyring SK, Trofatter KF Jr, et al. Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts. Antimicrob Agents Chemother 1998;42:789-94
24. Edwards L, Ferenczy A, Eron L, et al. Self-administered topical 5% imiquimod cream for external anogenital warts. Arch Dermatol 1998;134:25-30
25. Syed TA, Ahmadpour OA, Ahmad SA, Ahmad SH. Management of female genital warts with an analog of imiquimod 2% in cream: a randomized, double-blind, placebo-controlled study. J Dermatol 1998;25:429-33
26. Tyring SK, Arany I, Stanley MA, et al. A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod. J Infect Dis 1998;178:551-5
27. Syed TA, Hadi SM, Qureshi ZA, Ali SM, Kwah MS. Treatment of external genital warts in men with imiquimod 2% in cream. A placebo-controlled, double-blind study. J Infect 2000;41:148-51
28. British National Formulary, version 42, 2001. http://www.bnf.vhn.net/home
29. Lacey CJN, Goodall R, Tennvall GR, et al. for the Perstorp Pharma Genital Warts Clinical Trial Group. Randomised controlled trial and economic evaluation of patient applied podophyllotoxin solution or cream, or clinic applied podophyllin in the treatment of genital warts. Sex Transm Infect, 2003. In press
30. Maw R (chairperson). Issues and practicalities of treating genital warts in the community. Int J STD AIDS 2001;12(Suppl. 7):1-8
31. Strauss MJ, Khanna V, Koenig JD, et al. The cost of treating genital warts. Int J Dermatol 1996;35:340-8
32. Law AM, Kelton WD. Simulation modelling and analysis. New York: McGraw-Hill, 1991
33. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50:683-91
34. Alam M, Stiller M. Direct medical costs for surgical and medical treatment for condylomata acuminata. Arch Dermatol 2001;137:337-41
35. Langley PC, Tyring SK, Smith MH. The cost effectiveness of patient-applied versus provider-administered intervention strategies for the treatment of external genital warts. Am J Man Care 1999;5:69-77